OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2022-03-31-accounts

Bristol Drugs Project Limited

(A company limited by guarantee) Report and Financial Statements Year Ended 31 March 2022

Company No. 1902326
Charity No. 291714

Bristol Drugs Project Limited

Contents

For the year ended 31 March 2022
Page
Reference and administrative details 1
Chair's statement 2 - 3
Trustees' report 4 - 26
Independent auditors’ report 27 - 30
Statement of financial activities 31
Balance sheet 32
Statement of cash flows 33
Notes to the financial statements 34 - 51

Bristol Drugs Project Limited

Reference and administrative details

For the year ended 31 March 2022

Company number 01902326
Charity number 291714
Registered office and 11 Brunswick Square
operational address Bristol
BS2 8PE
Tel: 0117 987 6000
Trustees The trustees who served during the year and up to the date of this
report were as follows:
R Amos
K Barker
D Bradnock (Appointed 27 September 2021)
K Curling
M Lea, BA Hons, FCA, CTA
J Long QPM, BA Hons, MA (Chair)
R Mayall
R Paine
T Rice (Appointed 9 November 2021)
J Risk
T Smyth MRCGP FRCS
M Wilkinson (Appointed 9 November 2021)
Senior Management Team Maggie Telfer OBE, Chief Executive Officer
Rachel Ayres, Business Development Support Manager
Stephen Jackson, Service Manager (resigned 31 December 2021)
Shoba Ram, Service Manager
Kathryn Talboys, Service Manager
Bankers Unity Trust Bank plc Triodos Bank
Nine Brindleyplace Deanery Road
4 Oozells Square Bristol
Birmingham BS1 5AS
B1 2HB
Solicitors Gregg Latchams Ltd
7 Queen Square
Bristol
BS1 4JE
Auditors Godfrey Wilson Limited
Chartered accountants and statutory auditors
5th Floor Mariner House
62 Prince Street
Bristol
BS1 4QD

1

Report of the Trustees

For the year ended 31 March 2022

Bristol Drugs Project

Reference and administrative information set out on page 1 forms part of this report. The financial statements comply with current statutory requirements, the Memorandum and Articles of Association and the Statement of Recommended Practice - Accounting and Reporting by Charities (effective from January 2019).

CHAIR’S REPORT FOR THE YEAR ENDING 31[ST] MARCH 2022

Bristol Drugs Project is again able to report on a positive year for the charity during 2021/ 2022. The continued backdrop of the COVID-19 pandemic has required additional contingencies but, as the following report shows, these have not hindered BDP’s ability to provide excellent services for those people who need them. As I stated 12 months ago, the commitment and resilience amongst staff and volunteers have been key factors in this.

The charity last year reported on how it had risen to the challenges of COVID-19 through innovation and adaptability. To an extent these have been consolidated upon during 2021/ 2022. As we reported last year though, longer term planned service provision also continued to be strengthened through the contract extensions for ROADS and Targeted Youth Support. It is pleasing to note too that the work with young people, commenced in 2021 with New Leaf, has also been extended. At BDP’s strategic planning sessions during the autumn of 2022, Trustees restated a longer-term commitment to working with young people and families. Clearly, through these contracts, the involvement of BDP in this sphere provides a positive development of these aims.

The accounts for the year ending March 31st 2022 show that BDP made provision from reserves of £179,107 to cover reduced income and the adjustment to the national pay award 2.75% pay increase. Other factors though have contributed to a year end surplus of £87,617. For 2022/23, the tapered reduction in some of BDP’s contractual funding means it has again been decided to transfer from reserves, a sum to support the financial position during 2022/23. This is anticipated to be in the region of £230,000. BDP’s strategy is not to continue to sustain services through reserves but, in the short term, the rationale for doing this remains justified. It also allows the charity to meet its contractual commitments until it begins to enter into tendering processes for new arrangements from 2023 onwards.

Our report last year was anticipating Part 2 of Dame Carol Black’s 2-part Independent Review of Drugs, which was published on 8 July 2021. Part 1, published on 27 February 2020, provided analysis of the challenges posed by drug supply and demand. Part 2 focuses on drug treatment, recovery and prevention, all of which provide primary focusses for the work of BDP. As the Home Office comments, “The report’s aim is to make sure that vulnerable people with substance misuse problems get the support they need to recover and turn their lives around, in the community and in prison.” Its 32 recommendations for change are aimed at seeing improvements in the effectiveness of drug prevention and treatment, helping more people to recover from dependence. With its emphasis on multi-agency interventions and local accountability, BDP appears well-placed to continue and add to its work in these areas.

2

Bristol Drugs Project

Report of the Trustees

For the year ended 31 March 2022

On our Board of Trustees, we have been pleased to welcome new trustees, David Bradnock, Moyna Wilkinson, and Terry Rice, whose memberships were confirmed at our 2021 AGM. Towards the end of 2021, the Board was also joined by Dr Peter Godfrey, whose membership we hope to confirm at our next AGM. I believe this provides BDP with a full, committed, and broadly experienced Board of Trustees to support its work going forward.

I wish to thank all the staff and volunteers at BDP whose work, under the inspirational leadership of our CEO Maggie Telfer, has led to another year of significant achievement for the charity and allowed it again to provide high quality services to people who need them.

John Long

John Long QPM, BA Hons, MA

23 August 2022

3

Bristol Drugs Project

Report of the Trustees

For the year ended 31 March 2022

The Board of Trustees present their annual report and financial statements for the year ended 31 March 2022. The Trustees’ report also contains the Directors’ report, as required by the Companies Act 2006. This is an important document, which summarises Bristol Drugs Project’s activities during 2021/22; highlights key achievements; and identifies challenges and ambitions for 2022/23.

OBJECTIVES AND ACTIVITIES

Bristol Drugs Project’s (BDP) charitable purpose is described in the objects within the charity’s Memorandum and Articles of Association as:

Achievements & Performance – Delivering Public Benefit

This report describes how the charity’s activities fulfil the Public Benefit provisions of the Charities Act 2011. In doing this the charity has complied with the duty in section 4 of the Charities Act 2011 to have due regard to public benefit guidance published by the Charity Commission. The Board of Trustees is satisfied that BDP has charitable aims that are carried out for public benefit, specifically:

This report describes BDP’s activities transparently, documenting their relevance to our objects as a charity and demonstrating that BDP’s activities are effective in achieving the charity’s aims. BDP has reviewed any potential negative impact of its activities to satisfy itself that the benefits far outweigh any detriment or harm arising from the charity’s activities.

4

Bristol Drugs Project

Report of the Trustees

For the year ended 31 March 2022

For example, BDP takes active steps to minimise any potential harm arising from its Needle and Syringe Programme by placing emphasis on safe disposal of injecting equipment supplied by BDP in order to minimise the risks that can arise from inappropriate disposal.

The public benefit we create can be defined by:

Who We Provide Public Benefit For

BDP delivers services to individuals, families, and communities affected by drug, alcohol or other addiction, which reduce harm, maximise individuals’ potential and promote independence from drugs and alcohol.

For Adults:

BDP delivers services to adults through Bristol’s Recovery Orientated Alcohol & Drugs Service (ROADS) and other grants and donations. During 2021/22, 2,610 individual adults whose alcohol or drug use was problematic benefitted from services provided by BDP: this is an increase of 5.4 % compared with the previous year (2020/21: 2,476). The increase follows a return to higher levels of activity after lockdowns in the previous year. A proportion of these 2,610 people will have accessed more than one service or had more than one period of engagement during the year.

For Children & Young People:

BDP provides drug and alcohol-focused work with young people as part of Bristol’s Targeted Youth Service (TYS) for 11-18 year olds, delivered by Creative Youth Network (CYN). We contribute to delivering the ‘September Guarantee’ which aims to minimize the number of young people who are not in education, employment or training (NEET). 291 children were supported through 1-1 appointments, 122 in workshop settings and 750 through detached work.

5

Report of the Trustees

Bristol Drugs Project

For the year ended 31 March 2022

BDP also continued to support children under 11 years old through our charitably funded M32 Youth Groups, supporting 5-10 and 11-16 year olds respectively.

Referrals to Bristol’s Youth Alcohol and Drug Diversion (YADD) programme remained at a similar level to pre-pandemic periods with 48 referrals. The YADD programme offers an educational and supportive intervention as an alternative to a warning or caution for a first possession offence. Engagement remained high, with 75% of young people referred completing this alternative to a criminal justice ‘footprint’ and the negative impact this can have for young people’s future employment opportunities.

This was the second year of ‘New Leaf,’ offering longer-term support to young people whose cannabis use is problematic and who are at risk of Child Criminal Exploitation. We also secured new funding through the Vanguard programme to establish ‘New Leaf Rapid’ which offers intervention as an alternative to school exclusion for a drug-related in school.

How We Provide Public Benefit

10th March 2022 marked 36 years of providing effective services to people with alcohol or drug problems, designed to reduce harm, maximise individuals’ potential and promote independence from drugs and alcohol.

We continued to provide a multitude of interventions for people experiencing problems with alcohol or drugs, of all ages, at all stages of the complex process of behavioural change. The services we provide are tailored to individual need - not dictated by our workforce’s personal beliefs or a ‘one size fits all’ approach. BDP’s role is to support people in building their recovery capital (rewarding relationships, valued activity, adequate housing, and income). Supporting not judging; recognising the impact of Adverse Childhood Experiences with trauma-informed approaches; nurturing change with passion and ambition; and enabling people to acquire skills and self-belief, which makes recovery an enduring and rewarding reality.

At one end of the spectrum of change, we deliver services, which are designed to reduce drugrelated deaths, for example, our Needle and Syringe Programme, Naloxone supply to reduce fatal overdose, and a Physical Healthcare service to enable skin and soft tissue infections and other healthcare needs to be tackled early to reduce hospitalisation and harm.

At the other end of that spectrum, we deliver services which reconnect individuals with their family, community and life opportunities, as drug or alcohol dependence becomes part of their life rather than something which defines them.

All of the charity’s services are free at the point of delivery. They are provided at multiple locations, including 46 GP surgeries, youth and family centres, and through extensive outreach to ensure easy access for beneficiaries. Our Mobile Harm Reduction Service vehicle and our premises at Brunswick Court as well as our partner premises are compliant with the building provisions of the Disability Discrimination Act.

6

Report of the Trustees

For the year ended 31 March 2022

Bristol Drugs Project

Our People

Services were delivered by 67 full-time equivalent staff. Our volunteer support began to recover after being depleted by the reduced availability of people and BDP’s reduced opportunity for volunteering during reduced face-to-face contact with service users needed to maintain social distancing during COVID-19 lockdowns.

We were able to resume our Trainee programme in 2021 with five people with lived experience of problematic drug or alcohol use recruited in September 2021.

Throughout 2021/22 we continued to be supported to improve access to all of Bristol’s communities through our contract with Stand Against Racist Incidents (SARI). This included a new programme of virtual meetings with BDP staff, SARI, and experts helping us to explore issues troubling us, starting with ‘adultification’ which in plain language was our experience of older children with anti-social behaviours being treated as a problem rather than a child with needs.

Partnerships

During the year, BDP maintained our partnership working with Bristol City Council’s Public Health Team, our ROADS partners, Developing Health & Independence (DHI), the Homeless Healthcare Service and Avon & Wiltshire Mental Health Partnership Trust (AWP), the Office of Health Inclusion and Disparities (formerly Public Health England), 46 of Bristol’s GP Practices, Bristol City Council’s Children’s Services, the Youth Offending Team and Safer Options Teams, Bristol Secondary Schools, homelessness pathway housing providers, and a wide range of other voluntary and community sector providers to ensure delivery of effective services.

Drug and alcohol services have been impacted by a protracted period of austerity, with almost 25% reduction in funding, commencing in 2014. Partnerships can often suffer during periods of austerity as organisations retreat to core business and have limited appetite to share resources or develop new ways of working. We continue to work with others to develop relationships that really do produce more than the sum of their parts, sustaining mature ones and initiating new ones. New resources during the year through the ADDER programme enabled us to start a new partnership with Bristol City Council and Neighbourhood Policing teams to intervene early to reduce drug-related anti-social behaviour (ASB) in local authority housing stock.

A partnership working to develop more effective responses for people experiencing poor renal health was established towards the end of this period with a nephrology consultant and a new specialist nurse drug team at Southmead Hospital.

7

Report of the Trustees

Bristol Drugs Project

For the year ended 31 March 2022

This was year four of a number of our partnerships including: Creative Youth Network, with BDP delivering the drug and alcohol-focused activity within Bristol’s Targeted Youth Service, and BrisDoc Healthcare providing nursing resource within BDP’s Physical Healthcare service and delivering the rapid prescribing service for people who are homeless or discharged from hospital and not registered with a GP.

Our mature ROADS partnership with AWP continues and included sub-contracted delivery of Bristol’s rapid prescribing service for people on release from prison and the complex prescribing service within ROADS.

Our partnership with Bournemouth Symphony Orchestra who supported the emergence of Bristol’s Recovery Orchestra returned to real-time performances.

BDP continued to work closely at both strategic and operational levels with Bristol’s Golden Key programme, funded by The National Lottery Community Fund, in the penultimate year of its 8-year term. Golden Key works to improve the lives of people who experience multiple disadvantage – who form a significant proportion of our service users.

After a fallow year enforced by COVID-19, the 9th annual event to celebrate the lives of loved ones lost to drugs or alcohol, organised by Bristol Bereavement Through Addiction, of which BDP is a member, took place in November 2021. The support group at BDP, for people who have lost a loved one to a drug or alcohol-related death met virtually throughout the year, offering monthly, facilitated opportunities for people to seek and receive support from each other and attracting people from a wider geographical area.

Profile & Influence

Our Communications & Digital Engagement role has continued to help us to communicate the impact of what we do most effectively through print, digital and social media.

Our strong research partnerships continued during the year:

We facilitated research by the University of Leeds and Liverpool John Moores University, looking at people’s experiences of care when they are having problems with both their mental health and alcohol or drug use.

We also worked with research by the universities of Dundee, Stirling, Bristol and Ling’s Cross looking at understanding the contextual factors that impact on the effective provision of opiate substitution therapy (OST) and what works, for whom and under what circumstances.

8

For the year ended 31 March 2022

Bristol Drugs Project

Report of the Trustees

The Public Benefit We Provide

For adults, our activities included:

For April 2021 – March 2022, continuing to provide our central Advice Centre where people can be triaged and referred for a ROADS assessment; linked with other support services; and find a safe non-judgmental space with respite from often very harsh day-to-day lives where being homeless is an ever-present feature.

Harm reduction initiatives including: Needle and Syringe Programmes delivered within our Advice Centre and at 27 pharmacies; a mobile harm reduction service; early morning outreach to street drinkers; two Wet Clinics delivered in partnership with the Homeless Healthcare Service each week, supporting people drinking dependently, most of them homeless or vulnerably housed; outreach into local homelessness pathway providers and non-commissioned supported housing.

Our weekly women only session with child care continued but on a pre-booked basis to support social-distancing.

Our 50+ Group providing older people the opportunity to give and get support from their older peers continued to offer support to people whose main identity is as older people.

Our established group Prism – supporting people identifying as LGBTQ+ continued to meet weekly with a format of three therapeutic groups followed by a social group with content designed by participants.

As the night-time calendar cleared from autumn 2021, we built our harm reduction presence at venues, continued our partnership with Bristol Students Union and University of Bristol, and got planning for the return of festivals.

Our Opioid Substitution Treatment: one of the largest programmes in the UK, delivered in partnership with over 90% of Bristol GPs at 46 GP Practices . This makes it a genuine placebased service – offering easy access in the heart of communities right across Bristol . Our Link Worker roles – creating identity-based pathways into treatment are designed to support other organisations to identify people who could benefit from drug or alcohol treatment who are not currently being referred to or engaging with this. They deliver brief interventions and support engagement with treatment, as well as ensuring that services and communities have contemporary information about Bristol’s services and substances. Our three Link Workers role focus on Diverse Communities, People with mental ill health or learning disability and people engaged with Families in Focus (Strengthening Families).

Last but not least, our Creative Communities – Recovery Choir Rising Voices and Bristol Recovery Orchestra all suffered during the pandemic with real barriers to meeting. Real-time meetings returned during the year as well as performances, including a Rising Voices appearance at Golden Key’s annual awards ceremony in March 2022.

9

For the year ended 31 March 2022

Bristol Drugs Project

Report of the Trustees

Benefits for individuals

2,610 individual adults benefited from BDP’s services during 2021/22. Many engaged with more than one service and some people had more than one episode of treatment during the year. Of these 2,610 people:

Our profile of an ageing demographic is an increasingly prominent feature of drug and alcohol treatment populations across the UK, as well as in Bristol, and continues to inform our development of targeted services for older people, including a sharper focus on their physical health needs – arguably more pressing than their drug or alcohol issues.

Overall 26% (2020/21: 26%) of the people BDP supported during this year were female.

Overall, 5% were from Black, Asian or Minority Ethnic communities, just under 5% of mixed heritage, and 4% from other White European communities.

For 5.3% of people, English was not their first language (2021: 4.5%). 32 community languages in addition to English were spoken (2021: 30) and BDP continued to invest in translation and interpreter support particularly for people engaged by our Diverse Communities Link Worker. Browsealoud remains a feature of our website enabling translation of content into multiple languages which can be read or spoken enabling this to be as accessible as possible to people whose first language is not English, as well as to people whose hearing or sight is an issue for them.

4% of people identified as Lesbian Gay Bisexual Transgender or questioning; this is the same as the proportion in the previous year.

16% of people described themselves as having a disability.

72% of those who disclosed their religion reported having ‘no religion’ (2020/21: 69%). Religions included Baha’i, Buddhist, Christian, Hindu, Jain, Jewish, Muslim, Pagan, and Sikh.

10

Report of the Trustees

For the year ended 31 March 2022

Bristol Drugs Project

Heroin remains the most widely used main drug (79% of all those in treatment); however poly drug use, with heroin and crack cocaine used in combination, remains the most common pattern of usage, with 61% of people using heroin also using crack cocaine. This combined use of heroin and crack cocaine remains a particular feature of Bristol’s treatment population, with Bristol having the highest estimated prevalence of crack cocaine use per 1,000 population aged 16-64, of any area in England.

Just under 14% are living with children.

77% of people were living in secure housing (in a social housing tenancy, with family or owneroccupiers).

Just under 19% were in regular employment – a 2% rise from 2020/21.

People living in all areas of Bristol benefitted from BDP’s services with the largest populations living in eight Wards: Lawrence Hill; Hartcliffe & Withywood; Central; Filwood; Ashley; and then Southmead, Easton and Avonmouth & Lawrence Weston.

For children and young people, our activities included:

In partnership with Creative Youth Network, delivering specialist services as part of Bristol’s Targeted Youth Service with targeted interventions, normally of up to 12 weeks duration with children and young people aged 11-19 years (up to 24 with learning difficulty or disability).

Our two ‘M32’ Youth Groups – one for 5 to 10 year olds, the other for 11 to 16’s continued to meet monthly.

Continuing to deliver Bristol’s Youth Alcohol & Drug Diversion (YADD) project. The YADD programme offers under 18’s found in first possession of a substance controlled under the ‘Misuse of Drugs Act’ the opportunity to elect to have a personal, confidential education session with a BDP Youth Worker as an alternative to receiving a warning or caution. Referrals are received each week from Avon & Somerset Constabulary, most for possession of cannabis, but a small number for possession of Ketamine and MDMA. 45 young people were referred during the year – a similar number as in 2021/22.

We continued our New Leaf project to young people who have entrenched cannabis use and Child Criminal Exploitation involvement. We are grateful to the CHK Foundation who have invested their resources in this intervention in Bristol for a second year, enabling us to provide longer-term support for this particularly vulnerable population of children and young people whose cannabis use draws them into the fringes of drug market supply and the associated risks. We added a new project, New Leaf Rapid, which enabled us to offer this as an alternative to school exclusion in Bristol’s Secondary schools.

11

Bristol Drugs Project

Report of the Trustees

For the year ended 31 March 2022

Of the 291 children and young people supported through 1-2-1 Targeted Youth Support:

ACHIEVEMENTS AND PERFORMANCE

Demonstrating Effectiveness – Individuals & Communities

97% of adults engaged in treatment with BDP were retained in, or completed, treatment during 2021/22 – an increase from the 2020/21 performance of 94.5%.

BDP uses an outcome monitoring tool – the Treatment Outcome Profile (TOP) – which is in use across all adult treatment services in England, to demonstrate the impact of alcohol and drug treatment services. Public Health England estimate a benefit cost ratio for drug treatment of 4:1, i.e. every £1 spent on drug treatment saves £4 on crime and health care costs; for alcohol the ratio is 3:1, a saving of £3 for every £1 spent.

Demonstrating Effectiveness – Individuals, Families & Communities

TOP data after 6 months in treatment showed BDP performance, at 54%, exceeding the top end of the expected performance range for cessation of opiate (mostly heroin) use at 6 month review for people starting a new episode of treatment. The expected range for comparator providers’ was 38 – 52%. For cessation of crack cocaine use BDP achieved 50% (comparator providers’ range 32 – 48%). This is the fourth successive year of performance in excess of the range expected.

However, success isn’t just about quantity, and in addition to this increase in the number of people benefitting from drug or alcohol treatment services with a nationally prescribed successful outcome, it is feedback from individuals and our partners which really demonstrates the quality and impact of the services BDP delivers.

Adults told us:

About their previous Shared Care Worker

“She saved my life when I couldn't save myself.”

12

Bristol Drugs Project

Report of the Trustees

For the year ended 31 March 2022

Message from J about to start an inpatient detox

“3 days away it’s hitting me a bit now as it’s almost here. Thank you J and can you tell V and C (other Engagement Team Workers) thanks for everything to all of the team who supported me and gave me help. And my shared care worker. I know the hard bit will start when I get out of there. Thanks to you J as you have been a big help just making sure I stayed safe.”

Text message to BDP

“Just a little text to say thanks and that 7 years on I'm still sober all thanks to your help.”

Phone call to BDP

“So thankful for all the support (Shared Care Worker) has given him over the years. He said he has done a remarkable job and hopes that he can continue to help provide this support to many people in the situation he was in. He has the strength every day to keep going and stay clean because of all the work put into him.”

Letter from woman starting 12 month prison sentence

The reason I am staying in touch is because while you were supporting me at the BDP Centre, believe me when I say I felt heard, Supported and Safe and also respected. And my plan when I am out I should like to come back to the Women’s group so I just want to stay close and connected.

Children and Young People we support told us

E told me that he has not spoken to anyone before and he wanted to tell me everything from “the beginning”…. At the end of the session E told me that he felt much better, he felt a “release”.

A Mum told us about the impact our New Leaf project was having

“Brilliant school run with him, what a difference a Youth Worker makes lol thanks ever so much x.”

13

Bristol Drugs Project

Report of the Trustees

For the year ended 31 March 2022

Feedback from other organisations and partners also illustrates the value and effectiveness of our services and also our role in supporting other organisations to work effectively with people with drug and alcohol problems:

Feedback from research team following RECO Trial recruitment at BDP

“In all the interviews we conducted this week (27), we did not hear a bad word said about a Shared Care Worker, and I think that is a greater testament to the quality and passion that is put into the work at BDP, than anything we could ever say. The service users really look up to the staff, and the seeds they plant really do make a difference.”

Feedback after a BDP Behind The Scenes event from Police Officer

“I have dealt with students who brought a bag of ecstasy tablets into school and, sanctions aside, that was very much about managing the risk going forward as they had a lot going on. To that end, your message of harm reduction over zero tolerance is compelling, and something I always do my best to convey in any school classes I am asked to present. Your presentation will certainly assist me with that.”

Educating and enthusing the professionals of the future School of Pharmacy, Bath

“Thank you so much for all your support over the years. I cannot overstate how important the BDP visits have been to our course and how much the students have gained from this. You have always been so supportive, even in times of great crisis, like a global pandemic, you could have easily dropped us but instead you and the team adapted. That is hugely appreciated.”

Demonstrating Effectiveness: Reducing Drug-Related Deaths

Reducing Overdose

Despite being an area with one of the highest prevalence of opiate and crack cocaine users per 1,000 population in England, the combination of extensive needle and syringe supply, opioid substitution treatment and training in the use of Naloxone (which reverses opioid overdose) has meant that Bristol has had a rate of drug-related deaths which has been much lower than many other areas. New funding during the year though the ADDER programme enabled us to add the supply of Nasal Naloxone (Nyxoid) to its injectable form (Prenoxad). This is easier to carry as it is smaller and is more likely to be used by professionals who may feel reticent about using the injectable form of Naloxone. With continuing funding for nasal naloxone into 2022/23 we will be able to evaluate the impact of this additional resource to reduce drug related deaths in Bristol. Although experiencing a smaller increase in deaths than many other areas, we have still lost many people known to many staff at BDP for many years and the impact of deaths continues to be keenly felt by many.

Our commitment to supplying Naloxone remains very high with 1,353 doses supplied in the calendar year 2021 (2020: 1,024) in this period – a 32% increase in supply. The increase includes the supply of Nasal Naloxone from November 2021. Of the 1,353 doses of Naloxone

14

Bristol Drugs Project

Report of the Trustees

For the year ended 31 March 2022

supplied, 52, were replacement doses where it was reported that they had been used to ‘save a life’. Clearly not all overdoses would have been fatal, but some of these 52 would have been.

This remains impressive evidence of BDP’s effectiveness in reducing drug related deaths through accidental overdose, giving more people opportunity to benefit from support and move on to life beyond treatment.

Reducing Transmission of Blood-Borne Viruses

We continued our sharp post-COVID-19 lockdown focus, on ensuring Blood-Borne Virus (BBV) testing for Hepatitis C is offered to people every 12 months. The importance of this activity was highlighted in December 2021 when two people, who had not injected for a decade, were tested for the first time, both were positive for Hepatitis C and started treatment. Without testing and treatment both would have been at risk of dying prematurely.

Increasing Needle and Syringe supply

Coverage is a calculation aimed at assessing what percentage of People Who Inject Drugs (PWID) have access to a sterile needle and syringe for every injection, thereby removing the risk of BBV transmission through sharing. After growing coverage of needle and syringe supply to PWID, we have sought to understand post COVID-19 lockdown reduced activity at our Needle and Syringe Programme - a picture being seen nationally.

Safeguarding

Unlike many areas of the country, including other areas of Avon & Somerset Police Area, Bristol has not seen the level of expansion of ‘County Lines’ – where out of area dealers set up phone-based supplies, often involving ‘cuckooing’ – occupying a vulnerable adult’s accommodation to supply from and often involving coercion or escalating violence. However, existing dealing networks use similar methods and a number of vulnerable service users have been ‘cuckooed’ during the year. Our new ADDER-funded roles, intervening early where ASB is identified as drug-related, often involves supporting people being ‘cuckooed’.

We have continued to be an active player in Bristol’s approach to supporting young people at risk of, or experiencing, Child Criminal Exploitation and Child Sexual Exploitation. Contributing to local Safer Options meetings to co-ordinate involvement to support children and young people, and extending local support through our New Leaf and New Leaf Rapid projects working with young people whose entrenched cannabis use increases their vulnerability.

Challenging Prejudices

This underpins all that BDP does, both in our day-to-day work with one of the most marginalised groups in our society where health inequalities are stark, and in our relationships with other organisations. It was encouraging to see the 2021 new government drug strategy prioritise new funding for areas experiencing greatest deprivation.

15

Report of the Trustees

For the year ended 31 March 2022

Bristol Drugs Project

We take all opportunities to get involved in training current and future workforces to raise the needs of people with drug and alcohol problems and to highlight the impact of the prejudices they face, with examples for student pharmacists described earlier.

FINANCIAL REVIEW

The net financial result for the year shows a surplus of funds for the year of £87,617. This compares with a surplus of £69,883 in the previous year. This surplus has been achieved by increasing income by £115,915 against budget projections and by reduced expenditure directly related to the impact of COVID-19 on service delivery and recruitment challenges. The accumulated funds at the year-end totalled £3,984,490 (2021: £3,896,873). Restricted funds are £276,798 (2021: £150,790) and unrestricted funds were £3,707,692 (2021: £3,746,083).

Principal Funding Sources

Income received in 2021/22 was £3,822,381, 3% more than the income received in 2020/21 of £3,706,466. The higher income in 2021/22 was attributable to new funding through the ADDER programme for programmes to support adults, new funding through the Vanguard Programme to establish ‘New Leaf Rapid’ offering alternative intervention to school exclusion to children and young people for drug-related incidents support and grants, notably from St. Monica’s Trust to support BDP’s work with older people.

Of the full year’s income, £981,176 (2021: £965,787) was paid to partners for sub-contracted service delivery including payments to community pharmacies for delivery of Needle and Syringe Programmes, and to other sub-contractors AWP and BrisDoc Health Care.

The Board of Trustees would like to express its thanks to all the organisations that have provided funding, in particular Bristol City Council, which remains the charity’s largest funder; to the CHK Foundation with their grant for a second year for our New Leaf project; and the Arts Council, who supported our Creative Communities.

Investment Policy

Most of the charity’s funds are committed in the short-term, so there are few funds available for long-term investment. The Board of Trustees’ policy is to place any surplus funds, including unrestricted funds brought forward, on short-term bank deposit and has spread its deposits between Unity Trust Bank, Triodos Bank, and Cambridge & Counties Bank. The Board has reviewed this policy regularly throughout 2021/22 to ensure its effectiveness in meeting the needs of BDP’s beneficiaries and to fulfil the ‘duty of care’ of Board members. Towards the end of this period, BDP sought the services of a professional investment advisor to support a fundamental review of its investment strategy. The Trustee Board selected a preferred investment advisor partner and will work with them to review its investment policy to ensure the most effective stewardship of BDP’s resources during 2022/23 and beyond.

16

Report of the Trustees

For the year ended 31 March 2022

Bristol Drugs Project

Reserves Policy

As part of the annual planning and budget-setting cycle, the Board of Trustees review and approve the level of readily available reserves appropriate to the scale, complexity, and risk profile of BDP. The Finance and General Purposes Committee keep this under review. The provision made for lease dilapidation commitments remained at £166,000.

The Board of Trustees’ policy is to retain accumulated unrestricted funds in order to provide continuity of service in the event of: late payment of funds; where contract payments are made in arrears; unexpected contingency; to enable BDP to compete in competitive procurement processes against much larger market ‘players’; and to sustain priority activities in line with the charity’s objectives. The Board of Trustees have identified the need to retain unrestricted reserves necessary for 26 weeks operating costs, a budgeted figure of £1,618,061 for the financial year 2022/23. We can clearly demonstrate that we retain sufficient resources to deliver services with confidence and to manage any negative impact on government spending, which remains the major source of the charity’s income.

PRINCIPAL RISKS AND UNCERTAINTIES

The Board of Trustees considers and approves a risk map and management plan each year, which identifies the risks to which BDP may be exposed. The methodology used to assess risk evaluates these against 5 measures of likelihood of occurrence and 5 measures of impact. Mitigation measures are reviewed and a post evaluation score agreed with retained risks categorized as Red, Amber or Green. This risk register is reviewed regularly to ensure that: risk levels are appropriate; that new risks are identified; and that a management plan is in place to minimise and mitigate BDP’s exposure to those risks.

The Board of Trustees considers exceptional risks routinely at its meetings when it receives reports of emerging or unforeseen risks.

The main risks to the charity, which would constrain its ability to deliver services to people with alcohol and drug problems on the scale in which they are required, are:

Loss of funding

BDP mitigates this risk by providing high quality and effective services which are valued by commissioners, attractive to prospective commissioners, and credible and effective for people with alcohol or drug problems and people in those communities which are impacted by these. New funding is difficult to secure as Public Sector funding continues to decrease but BDP continues to seek to diversify its funding base to increase resilience, while recognising that securing income on the scale required to deliver reliable services to vulnerable adults and children from sources other than the Public Sector is not realistic. The charity’s main funding derives from ROADS and Targeted Youth Services (TYS). ROADS is a fixed value contract which was extended to January 2025 this year, at the year five funding value, TYS contract was confirmed for a fifth and final year to May 2023, with a further tapered

17

Report of the Trustees

For the year ended 31 March 2022

Bristol Drugs Project

reduction of almost 10%. BDP’s prudent planning has ensured that the charity has sufficient reserves to mitigate the impact of reduced funding of these two major sources of income.

Disaster & Business Continuity

An ‘Emergency Response Planning Document: Business Continuity’ sets out BDP’s response to disaster situations. BDP reviewed this policy regularly. During the year BDP continued to review risk planning procedures to mitigate the impact of COVID-19 and ensure that BDP has been able to operate safely within Government guidance, which changed on multiple occasions during 2021/22. The views of staff are actively sought as part of regular COVID-19 risk assessments undertaken on a monthly cycle or when there was any significant change to guidance. All BDP spaces were assessed for maximum occupancy to ensure social distancing; sanitising regimes are in place and visual materials developed to augment national COVID-19 messaging and changed regularly to avoid these becoming ‘wallpaper’ and overlooked.

Insurance cover is reviewed annually to ensure it is both sufficient for BDP’s risks and provides value for money.

Reputational Damage

Policies, procedures, audit, complaints procedures, and open communication mitigate risk of commissioners, current and potential service users and other organisations losing confidence in the organisation. BDP is held in high regard by service users, commissioners and other organisations as evidenced throughout this report.

PLANS FOR FUTURE PERIODS

We will be refocusing BDP’s strategic direction and priorities to ensure that the charity can continue to flourish and to set new challenges.

Although the peak of COVID-19 impact has passed, we will continue to be vigilant to the harm that some adults and children have experienced during lockdowns, including deteriorating mental health, domestic abuse, child neglect, abuse or exploitation, and the generational impact that lost schooling and work opportunities may have for young people and young adults.

COVID-19 has also shone a spotlight on health inequalities. Supporting people who experience profound health inequality, dying prematurely through the direct or indirect impact of alcohol or drug use, compounded for some by homelessness, mental ill health, absence of work opportunities and income, will continue to be at the heart of all we do. This following year will be one where we use our skills, learning, passion, and partnerships to make a bigger difference to more people’s lives.

18

Report of the Trustees

For the year ended 31 March 2022

Bristol Drugs Project

Workforce

In common with other drug and alcohol services in other areas of the country and most other sectors - from healthcare to hospitality, we have experienced recruitment challenges. These are likely to continue through 2022/23 and hence recruiting and retaining staff will be a key priority for 2022/23.

All indications are that inflation will continue to rise. It will clearly have greatest impact for the most disadvantaged, including many of BDP’s service users. We will continue to grow our skilled and passionate workforce, ensuring that their knowledge of related issues – benefits, housing, and money and debt management is ‘good enough’ to support people effectively. These issues are everybody’s business.

We will recruit our eighth ‘batch’ of trainees during 2022/23 – people with a recent personal history of problematic drug or alcohol use who face significant barriers to employment – usually a challenging criminal record. We will ensure that these trainees are equipped by BDP to follow in the footsteps of others. They will develop ‘on the job’ experience and skills and gain a Level Three qualification in a new partnership with Weston College which equips them to apply for work in this field or related housing or social care and increases lived experience within BDPs and others’ workforces.

Children and Young People

In the final year of Bristol’s Targeted Youth Support (TYS) and of youth services in their current form, we will contribute with other young people’s services, including the Youth Council established last year, to the future shape of support services for young people across our city. The needs of young people experiencing difficulty with drugs or alcohol and particularly those Children Affected by Substances (CABS) are often overlooked in strategies and services and we will continue to shine a light on their needs.

Treatment and Support

Many of our ambitions for 2022/23 are the same as last and previous periods. This is not because of failure of our plans but the reality that we are working with one of the most complex and ‘wicked’ problems of our age, where drug markets continue to diversify and thrive; where people’s route to change is made more difficult by lack of housing and work opportunity; where people’s support networks shrink with ageing; where their health deteriorates; and where stigma is alive and well. At the heart of change for many people using opiates also lie Adverse Childhood Experiences for which opiates in particular provide a learned coping mechanism, embedded over many years. Improving our ability to support people who have experienced trauma, supporting them to develop alternative less harmful coping mechanisms will continue to underpin our activities. New psychologist involvement funded through the new ADDER programme will bring new skills to support our Shared Care Team in particular to help people they support to locate those less harmful coping mechanisms and move out of treatment into a new period of their lives.

19

Report of the Trustees

For the year ended 31 March 2022

Bristol Drugs Project

Increasing successful treatment completions and growing the proportion of Bristol’s estimated alcohol and drug dependent populations who are engaged in treatment are key objectives for every year, and are even more important during 2022/23.

The most recent estimate of the population of people dependent on opiates in Bristol is 4,130 people. Although the proportion of Bristol’s estimated population compares well with a national picture, and if looked at over a number of years, is higher, we seek to be more ambitious in uniting opiate users with the benefits of treatment, specifically Opioid Substitution Treatment. However, simply to provide accessible services, easy to access through 46 GP surgeries, with short waiting times is not enough to engage and retain another ‘segment’ of opiate users; put simply, if people don’t come, they don’t come and it is time to do something differently.

So a priority for 2022/23 is understanding the barriers people see in accessing treatment, lowering those barriers and developing messaging and images to ‘sell treatment’ to people who don’t currently find it attractive.

Other priorities include:

Reducing deaths and improving health and wellbeing

As referenced earlier in this report, a significant proportion of our service users have undiagnosed or untreated health conditions – with respiratory illnesses featuring frequently. Opiates in particular suppress pain or symptoms associated with many health conditions and BDP has a key role to play in improving people’s health, including providing BBV and other testing, Hepatitis B vaccination, smoking cessation, and supporting pathways into primary and secondary care. Our enhanced nursing time, sub-contracted from BrisDoc Healthcare, will enable us to improve significantly access to physical health care, including wound care ‘there and then’ for our vulnerable population. We will also build on embryonic partnerships with the Renal Unit at Southmead Hospital to identify opportunities to detect renal ill health earlier and reduce shockingly high levels of mortality from renal failure experienced by people dependent on drugs or alcohol. A further year’s funding for Nasal Naloxone will enable us to further expand supplies to ensure it is on hand to reverse opiate overdoses.

Enabling increased access to detoxification from alcohol within an individual’s GP Practice

This has been difficult to establish post-COVID-19 – context changes in Primary Care. We will renew our efforts to embed this service within GP Practices.

Increasing contact with people using non-opiate drugs and alcohol in the night-time

economy

We will continue to polish our digital harm reduction activity so that, we continue to support people to reduce avoidable risk and harm linked with using non-opiates and alcohol. This will include continuing our partnership with the University of Bristol and Bristol Students Union to support harm reduction-driven policy. We also look forward to hosting and supporting The Loop to deliver their first licenced Drug Safety Checking service in the UK, here in Bristol.

20

Report of the Trustees

For the year ended 31 March 2022

Bristol Drugs Project

Improving access to Hepatitis C treatments

BDP will continue to use the World Health Organisation (WHO) commitment to eliminating Hepatitis C to underpin our harm reduction work as we commit to increasing further, coverage of our Needle & Syringe Programme through a wider range of routes, including home delivery; increasing the number of Bristol’s estimated population of People Who Inject Drugs engaged with Opioid Substitution Treatment; and increasing the number of people who start and successfully complete Hepatitis C treatment. To support increased numbers engaging in treatment we have appointed a dedicated worker to support people to engage with and complete this life-saving intervention.

Reducing Stigma

Stigma remains the highest barrier to accessing treatment and recovery for many of our service users. For people from some BAME communities that stigma can seem insurmountable. We will continue to work alongside communities through our Diverse Communities Link Worker role, developing our Community Champion role to offer a bridge between people who need treatment, and BDP’s and wider ROADS’ services.

Drug Control and Drug Market Changes

We will keep our radar finely attuned to shifts in drug markets and outbreaks of, especially heroin in the UK, which historically have been aligned with periods of increased austerity, and disrupted education, which we may face following the pandemic.

Research

We remain committed to developing and using the evidence of what works and research partnerships offer us a great opportunity to grow that evidence. We are particularly excited about a collaboration in 2022/23 which includes piloting use of crack pipes as a harm reduction measure.

National & Local Drug Policy, Strategy & Legislation

Publication of a new government drug strategy at the end of 2021- “From Harm to Hope” looks to reverse the significant funding reductions in drug treatment made during the 2000’s. Of particular note is its 10-year term, signalling once again government recognition that drug problems cannot be fixed in the short term. Bristol is a year one beneficiary of new investment.

Although welcoming renewed government interest, the strategy has two key areas of concern:

21

Report of the Trustees For the year ended 31 March 2022

Bristol Drugs Project

In Conclusion

We will continue to remain vigilant to drug-market, policy, strategy and legislative changes that will impact people with alcohol and drug problems, their families and their communities. We will challenge policy changes which will increase harm and stigma. We will ensure that our workforce is flexible, knowledgeable about areas previously seen as ‘specialist’, like housing and benefits and able to advocate to reduce the harmful impact of a bleak financial outlook and the health inequalities which our service users experience.

We will also seek to secure a more solid basis for our activities which are additional to those formally commissioned, but which add real value to people and communities. These include our Youth Groups, and our Creative Communities which offers of drama, choir and orchestra, adding a precious dimension to BDP’s work. We will also sustain and grow our work with populations facing specific barriers to finding help – including LGBTQ+ people, people with a learning disability, Older People, and Black, Asian and Minority Ethnic people.

Our biggest challenge and priority for the forthcoming year remains to seek and create new ways of connecting with people who are experiencing problems with their own or another’s alcohol or drug use, both those who fall in and out of treatment and those who see treatment as ‘not for them’. We commit to reaching more of that population in 2022/23 and recognise that this requires listening closely to what people want and then delivering with care, passion and creativity.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing Document

Bristol Drugs Project is a charitable company limited by guarantee, incorporated on 3[rd] April 1985 and registered as a charity on 14[th] May 1985.

The company was established under a Memorandum of Association that founded the objects and powers of the charitable company, and is governed under its Articles of Association. The Directors have commenced a review of the Memorandum and Articles of Association to ensure that, as well as being compliant with the Charities Act 2011 and Companies Act 2006, they are relevant to current patterns of drug and alcohol use, and contemporary policy. A key outcome sought is to bring them up-to-date with current, modern terminology. The Directors proposed changes to the Charity Commission and received their agreement to these in March 2022, these will be considered for adoption at the AGM in 2022.

22

Report of the Trustees

For the year ended 31 March 2022

Bristol Drugs Project

In the event of the company being wound up, members are required to contribute an amount not exceeding £1 each.

Board of Trustees (Directors)

The Directors of the company are also charity Trustees for the purpose of charity law and under the company’s Memorandum and Articles of Association are known as members of the Board of Trustees.

The Board of Trustees can have a minimum of 4 and a maximum of 15 members. The Board are very active, meeting approximately every 6 weeks, and are responsible for the strategic direction and policy of the charity, and for ensuring that its finances, systems and procedures are ‘fit for purpose’ as set out in its Governance Framework. In addition, to adherence to the ‘Nolan Principles’ – the seven principles of public life – Board members bring a wide range of business and professional skills to their role. The involvement of former service users as Trustees is particularly important, ensuring the needs of beneficiaries of the charity are at the core of BDP policy and strategy.

At the year-end, the Board of Trustees had 12 members from a variety of backgrounds relevant to the charity and its management.

The Board of Trustees delegates operational management of the charity to a Chief Executive, who in turn delegates responsibility for specific areas of service delivery, performance, and staff and volunteer management to senior managers.

Recruitment and Appointment and Changes to Board of Trustees

The charity operates a competency-based recruitment process, recruiting new Board members as required. Prospective Board members are interviewed by the Chair and Chief Executive and invited to observe a Board meeting(s). The Board of Trustees then decides whether to invite a new member to join them and to stand for election at the next AGM.

The Memorandum and Articles require a third of the membership of the Board to retire annually, although they may stand for re-election at the next Annual General Meeting.

Each Trustee may normally serve for three terms of office, although any Trustee may be asked to continue beyond this where the Board wishes to retain an individual’s specific skills for an additional term for the benefit of the charity. BDP seeks to achieve a balance between longer-serving Trustees who use their ‘collective memory’ to provide continuity to BDP’s work and newly recruited Trustees who strengthen skills and bring fresh perspective to the charity. David Bradnock, who retired in 2020 from a police liaison role with Bristol City Council Public Health Team, joined the Board in March 2021 and will stand for election at the next AGM.

23

Report of the Trustees

For the year ended 31 March 2022

Bristol Drugs Project

Board of Trustees Induction and Training

All applicants for the Board of Trustees receive a Recruitment Pack which gives a role description, detailed information about the charity’s history, services, and staff, as well as their obligations as Board members. All are given the Charity Commission’s guide ‘The Essential Trustee’ together with a copy of BDP’s Memorandum and Articles of Association and the latest financial statements. New members are encouraged to shadow services, though the need to maintain social-distancing in service delivery has limited opportunities for Trustees to do this during this year, and to participate in the charity’s annual service planning and review day and in-house training; this enables them to gain an in-depth understanding of the charity’s main activities to inform their decision-making.

Alternate Board meetings are preceded by an additional hour-long session, which focuses on a particular aspect of service delivery or relevant changes at national or local policy level. This enables Trustees to review regularly key issues affecting the future direction of the charity and to ensure that due weight is given to key changes in government policy, structures or changes in patterns of alcohol or drug use. Trustees also held two in-person, half-day strategic planning meetings where external facilitation supported them in identifying challenges and agreeing shared priorities for the charity.

Board of Trustees’ Sub Committees

Members are encouraged to become members of either the Finance and General Purposes Committee or the Quality and Clinical Governance Committee.

The charity’s Finance and General Purposes Committee, has delegated authority from the Board of Trustees and meets normally every six weeks to review financial performance, recommend any actions necessary to control financial risk, ensure service delivery within budget and agree significant capital expenditure. Members are Mike Lea, John Long, Kathy Curling, Kerry Barker and Rod Mayall. Quality and Clinical Governance Committee is chaired by Dr. Tom Smyth, a retired GP, with members Rozzy Amos, David Bradnock, Robin Paine, and Jennifer Risk. This committee has delegated authority from the Board to ensure adequate and appropriate governance structures, processes and controls are in place throughout BDP to promote safe, high quality care; achieve continuous improvement of care; and to ensure the effective and efficient use of resources through evidence-based practice and research.

Senior Leadership Team

This comprises the Chief Executive, three Service Managers, and our Policy & Quality Lead. They are responsible for delivering BDP’s Strategic Plan. Operational decisions are made by the Senior Leadership Team structure at fortnightly meetings. The Senior Leadership Team is considered to be the key management personnel of the charity. Regular Senior Management Team meetings, which include Team Leaders ensure effective communication and planning.

The remuneration of all BDP employees, including key management personnel is determined by BDP’s bespoke pay structure. This sets out five pay scales with lower and upper limits, each

24

Report of the Trustees

Bristol Drugs Project

For the year ended 31 March 2022

linked to different roles within the organisation, including Service Managers and the CEO. The charity periodically reviews its pay structure to ensure that remuneration for roles is broadly in line with that offered by other organisations delivering similar activities, most recently completed in February 2022.

Related Parties

Board of Trustees and Senior Staff declare potential conflicts of interest to BDP annually, or when their circumstances change. Conflicts of interest relevant to the business of meetings are asked for by the Chair and declared as a standard agenda item at all Trustee meetings.

Maggie Telfer, CEO, is a Director of Social Impact Bristol, a Special Purpose Vehicle established with St Mungo’s and Second Step to deliver Bristol’s Social Impact Bond for people with an experience of entrenched rough sleeping, which ceased operation in March 2022 as the contract for this service reached the end of its term.

Fundraising Policy

BDP did not employ professional fundraisers or commercial participators during this or previous periods and therefore the provisions of the Charity (Protection and Social Investment) Act 2016 do not apply to the charity’s activities.

BOARD OF TRUSTEES’ RESPONSIBILITIES

The Trustees (who are also Directors of the charity for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102: The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charity and of the income and expenditure of the charity for that period. In preparing those financial statements the Trustees are required to:

25

Report of the Trustees For the year ended 31 March 2022

Bristol Drugs Project

The Board of Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

All the current Board of Trustees members have taken all the steps that they ought to have taken to make themselves aware of any information needed by the company’s auditors for the purposes of their audit and to establish that the auditors are aware of that information. The Board of Trustees are not aware of any relevant audit information of which the auditors are unaware.

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Auditors

Godfrey Wilson Limited were re-appointed as auditors to the charitable company during the year and have expressed their willingness to continue in that capacity.

This report, including the Trustees’ Report, was approved by the Board of Trustees on 23[rd] August 2022 and signed on its behalf by:

John Long

John Long, Chair, QPM, BA Hons, MA 11 Brunswick Square Bristol BS2 8PE

26

Independent auditors' report

To the members of

Bristol Drugs Project Limited

Opinion

We have audited the financial statements of Bristol Drugs Project Limited (the 'charity') for the year ended 31 March 2022 which comprise the statement of financial activities, balance sheet, statement of cash flows and the related notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102: The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the annual report other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

27

Independent auditors' report

To the members of

Bristol Drugs Project Limited

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinion on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charity and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees’ report. We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

Responsibilities of the trustees

As explained more fully in the trustees’ responsibilities statement set out in the trustees’ report, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

28

Independent auditors' report

To the members of

Bristol Drugs Project Limited

Our responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The procedures we carried out and the extent to which they are capable of detecting irregularities, including fraud, are detailed below:

(1) We obtained an understanding of the legal and regulatory framework that the charity operates in, and assessed the risk of non-compliance with applicable laws and regulations. Throughout the audit, we remained alert to possible indications of non-compliance.

(2) We reviewed the charity’s policies and procedures in relation to:

(3) We inspected the minutes of trustee meetings.

(4) We enquired about any non-routine communication with regulators and reviewed any reports made to them.

(5) We reviewed the financial statement disclosures and assessed their compliance with applicable laws and regulations.

(6) We performed analytical procedures to identify any unusual or unexpected transactions or balances that may indicate a risk of material fraud or error.

(7) We assessed the risk of fraud through management override of controls and carried out procedures to address this risk. Our procedures included:

▪Testing the appropriateness of journal entries;

▪Assessing judgements and accounting estimates for potential bias;

▪Reviewing related party transactions; and

▪Testing transactions that are unusual or outside the normal course of business.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. Irregularities that arise due to fraud can be even harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

29

Independent auditors' report

To the members of

Bristol Drugs Project Limited

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

Use of our report

This report is made solely to the charityʼs members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charityʼs members those matters we are required to state to them in an auditorʼs report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charityʼs members as a body, for our audit work, for this report, or for the opinions we have formed.

Alison Godfrey

Date: 23 August 2022

Alison Godfrey FCA (Senior Statutory Auditor)

For and on behalf of:

GODFREY WILSON LIMITED

Chartered accountants and statutory auditors 5th Floor Mariner House 62 Prince Street Bristol BS1 4QD

30

Bristol Drugs Project Limited

Statement of financial activities (incorporating an income and expenditure account)

For the year ended 31 March 2022

Note
Income from:
Donations and legacies
Charitable activities
4
Other trading activities
Investments
Total income
Expenditure on:
Charitable activities: provision of services
Total expenditure
7
Net income / (expenditure)
Transfers between funds
Net movement in funds
5
Reconciliation of funds:
Total funds brought forward
Total funds carried forward		 Unrestricted
£
40,192
182,369
-
14,128
236,689
(275,080)
(275,080)
(38,391)
-
(38,391)
3,746,083
3,707,692		 Restricted
£
10,120
3,573,892
1,680
-
3,585,692
(3,459,684)
(3,459,684)
126,008
-
126,008
150,790
276,798		 2022
Total
£
50,312
3,756,261
1,680
14,128
3,822,381
(3,734,764)
(3,734,764)
87,617
-
87,617
3,896,873
3,984,490		 2021
Total
£
115,236
3,574,904
461
15,865
3,706,466
(3,636,583)
(3,636,583)
69,883
-
69,883
3,826,990
3,896,873

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in note 15 to the accounts.

31

Bristol Drugs Project Limited

Balance sheet

For the year ended 31 March 2022

Note
Fixed assets
Tangible assets
8
Investments
9
Current assets
Debtors
10
Current asset investments
Cash at bank and in hand
Liabilities
Creditors: amounts falling due within 1 year
11
Net current assets
Total assets less current liabilities
Provisions for liabilities
12
Net assets
14
Funds
15
Restricted funds
Unrestricted funds:
Designated funds
General funds
Total charity funds		 £
80,982
2,616,397
2,088,734
4,786,113
(668,158)		 2022
£
16,535
16,000
32,535
4,117,955
4,150,490
(166,000)
3,984,490
276,798
9,617
3,698,075
3,984,490		 2021
£
27,104
16,000
43,104
317,441
2,602,323
1,395,238
4,315,002
(295,233)
4,019,769
4,062,873
(166,000)
3,896,873
150,790
(856)
3,746,939
3,896,873

These accounts have been prepared in accordance with the special provisions applicable to companies subject to the small companies' regime.

Approved by the trustees on 23 August 2022 and signed on their behalf by

John Long

Kathy Curling

J Long - Director and Chair K Curling - Director

32

Bristol Drugs Project Limited

Statement of cash flows

For the year ended 31 March 2022

Cash flows from operating activities:
Net movement in funds:
Adjustments for:
Interest received
Depreciation
(Increase) / decrease in debtors
Increase / (decrease) in creditors
Increase in provisions
Net cash provided by / (used in) operating activities
Cash flows from investing activities:
Interest received
Net cash provided by investing activities
Increase / (decrease) in cash and cash equivalents in the year
Cash and cash equivalents at the beginning of the year
Cash and cash equivalents at the end of the year
Analysed as:
Cash at bank and in hand
Current asset investments		 2022
£
87,617
(14,128)
10,569
236,459
372,925
-
693,442
14,128
14,128
707,570
3,997,561
4,705,131
2,088,734
2,616,397
4,705,131		 2021
£
69,883
(15,865)
16,352
(261,025)
(69,903)
51,584
(208,974)
15,865
15,865
(193,109)
4,190,670
3,997,561
1,395,238
2,602,323
3,997,561

Analysis of changes in net debt

The charity has not provided an analysis of changes in net debt as it does not have any long term financing arrangements.

33

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2022

1. Company status

The address of the registered office is 11 Brunswick Square, Bristol, BS2 8PE.

2. Accounting policies

a) Statement of compliance

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006. There are no material departures from the SORP and FRS 102.

The charity meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value, unless otherwise stated in the relevant accounting policy note. The accounts are presented in sterling which is also the functional currency of the charity.

b) Going concern basis of accounting

The accounts have been prepared on the assumption that the charity is able to continue as a going concern, which the trustees consider appropriate. The charity holds unrestricted, general reserves of £3,698,075 and a cash balance of £4,705,131. There are no material uncertainties about the charity's ability to continue as a going concern.

c) Income

Incoming resources represent the amount derived from contracts, grants and donations receivable during the year. All income is credited to revenue when the charity is entitled to the income, any performance conditions have been met, it is probable that the income will be received and the amount can be measured reliably.

Many of the charity's funding streams, whilst having certain conditions attached which must be met to fulfil the charity's obligations, are actually contracts for service. Thus by providing the service for the year, the obligation attached to the contract is released with any residual deficit or benefit on the contract value being at the risk of or for the benefit of the charity. Income received in advance of provision of services under contracts is deferred until criteria for income recognition are met.

34

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2022

2. Accounting policies (continued)

c) Income (continued)

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

d) Expenditure and irrecoverable VAT

Expenditure is included in the financial statements on an accruals basis. Expenditure is charged directly to the provision of services wherever possible.

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

e) Allocation of support and governance costs

Support costs are those functions that assist the work of the charity but do not directly undertake charitable activities. Governance costs are the costs associated with the governance arrangements of the charity, including the costs of complying with constitutional and statutory requirements and any costs associated with the strategic management of the charity’s activities. All costs are allocated between the expenditure categories of the statement of financial activities on a basis designed to reflect the use of the resource. Costs relating to a particular activity are allocated directly, together with fair allocation of management and support costs on an employee basis.

f) Funds

Unrestricted general funds are available for use at the discretion of the board of trustees in furtherance of the general objectives of the charity.

Restricted funds are funds which have been given for a specific purpose by the donor or statutory body or by the purpose of the appeal in which the funds are raised. Expenditure which meets these criteria is charged to the fund, together with fair allocation of management and support costs on an employee basis.

Designated funds are unrestricted funds of the charity which the trustees have decided at their discretion to set aside to use for a specific purpose.

g) Tangible fixed assets

Depreciation of fixed assets is calculated to write off their cost less any residual value over their estimated useful lives as follows:

Motor vehicles, fixtures, fittings and office equipment are depreciated on a straight line basis over 5 years.

Assets are capitalised where the cost exceeds £5,000. A full year’s depreciation is charged in the year of acquisition.

35

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2022

2. Accounting policies (continued)

h) Investments

Investments in associated companies are held at cost, less provision for any impairment.

i) Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

j) Current asset investments

Current asset investments consist of cash held on deposit in interest bearing accounts. Such investments are measured at their fair value.

k) Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

l) Creditors

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

m) Leases and hire purchase contracts

Rentals paid under operating leases are charged to the statement of financial activities as they fall due.

n) Pensions

The charity operates a defined contribution pension scheme, and the pension charge represents the amounts payable by the charity to the fund in respect of the year. The assets of the scheme are held separately from those of the charity in an independently administered fund. The pension cost charge represents contributions payable by the charity to the fund and amounted to £35,882 (2021: £35,988). Contributions totalling £6,812 (2021: £8,678) were payable to the fund at the balance sheet date and are included in creditors.

o) Provisions

A provision is recognised in the balance sheet when the charity has a present legal or constructive obligation as a result of a past event, that can be reliably measured and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are recognised at the best estimate of the amount required to settle the obligation at the reporting date.

p) Financial instruments

The charity only has financial assets and financial liabilities that qualify as basic financial instruments, being trade and other debtors and creditors. Basic financial instruments are initially recognised at transaction value, and are subsequently recognised at their settlement value. Any losses arising from impairment (‘doubtful debts’) are recognised in the statement of financial activities. The amount of impairment loss recognised in the year is £nil (2021: £nil).

36

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2022

2. Accounting policies (continued)

q) Critical accounting judgements and key

In the application of the charity’s accounting policies, which are described above, the board of trustees is required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

The following are the critical judgements and estimates that the trustees have made in the process of applying the charity’s accounting policies and that have the most significant effect on the amounts recognised in the financial statements.

Provisions for lease dilapidations are recognised when a reliable estimate of the outflow of future economic benefit which will be required to settle any future obligation can be made. Further detail is provided in note 12.

Key management personnel are considered to be the board of trustees and the senior management team. As trustees, the board of trustees is not remunerated. The remuneration of key management personnel is disclosed in note 6.

3. Prior period comparatives: statement of financial activities

Income from:
Donations and legacies
Charitable activities
Other trading activities
Investments
Total income
Expenditure on:
Charitable activities
Total expenditure
Net expenditure
Transfers between funds
Net movement in funds		 Unrestricted
funds
£
98,744
226,431
461
15,865
341,501
(342,580)
(342,580)
(1,079)
(1,015)
(2,094)		 £
16,492
3,348,473
-
-
3,364,965
(3,294,003)
(3,294,003)
70,962
1,015
71,977
Restricted
funds		 2021 Total
£
115,236
3,574,904
461
15,865
3,706,466
(3,636,583)
(3,636,583)
69,883
-
69,883

37

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2022

4. Income from charitable activities

Age UK (St. Monica's Trust)
Bridge View Medical
Bristol City Council (ADDER)
Bristol City Council (ROADS)
CHK Foundation
Creative Youth Network
NHS BNSSG CCG (Vanguard)
Rough Sleeping Drug Alcohol Treatment Grant
(Street Intervention)
Rough Sleeping Drug Alcohol Treatment Grant
(Substance Misuse Liaison Connect)
Second Step
Other charitable income less than £5,001
Total income from charitable activities
Prior period comparative
Bridge View Medical
Bristol City Council (ROADS)
Bristol City Council (Social Impact Bond)
Bristol City Council (YADD)
CHK Foundation
Creative Communities
Creative Youth Network
Gilead Sciences (Terrence Higgins Trust)
Second Step
Youth Groups
Other charitable income less than £5,001
Total income from charitable activities		 £
8,190
7,924
-
-
-
142,144
8,501
-
-
9,204
6,406
182,369
£
7,750
-
29,548
1,913
-
-
143,451
-
36,817
-
6,952
226,431
Unrestricted
funds
Unrestricted
funds		 Restricted
funds
£
-
-
212,172
3,271,861
(11,142)
-
-
35,000
62,051
-
3,950
3,573,892
Restricted
funds
£
-
3,282,199
-
-
30,000
9,105
-
16,432
-
3,600
7,137
3,348,473		 2022 Total
£
8,190
7,924
212,172
3,271,861
(11,142)
142,144
8,501
35,000
62,051
9,204
10,356
3,756,261
2021 Total
£
7,750
3,282,199
29,548
1,913
30,000
9,105
143,451
16,432
36,817
3,600
14,089
3,574,904

Government grants

The charity received no government grants in the current period. During the year ended 31 March 2021 the charity received government grants defined as funding from Arts Council England to fund charitable activities. The total value of such grants in the period ending 31 March 2021 was £634. There are no unfulfilled conditions or contingencies attaching to these grants.

38

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2022

5. Net movement in funds

Net movement in funds are stated after charging:

Depreciation of tangible fixed assets
Auditors' remuneration:
Trustees' remuneration
Trustees' reimbursed expenses
Trustees' indemnity insurance
Operating lease payments:
Rent
Equipment		 2022
£
10,569
8,760
Nil
Nil
725
99,855
4,531		 2021
£
16,352
8,400
Nil
Nil
628
94,045
6,039

6. Salaries Staff costs were as follows:

Gross salaries
Employers national insurance
Pensions		 2022
£
1,882,655
165,824
35,268
2,083,747		 2021
£
1,845,815
158,880
35,988
2,040,683

One employee earned a salary in the range of £60,000 - £70,000 per annum (2021: one).

Included within gross salaries is one ex gratia payment of £10,842 which has been funded from unrestricted general funds.

Average number of employees (full time equivalent)
Average number of employees (headcount)		 2022
No.
67
74		 2021
No.
69
79

The total remuneration of key management personnel amounted to £236,270 (2021: £227,475).

39

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2022

7. Expenditure on charitable activities

Staff Costs
External Supervision
Legal and Professional
Recruitment
Salaries, Employer's NI and Pensions
Staff Benefits and Childcare Vouchers
Training and Development
Travel and Subsistence
Direct Service Costs
Breaking Free/SARI
Client Service Access and Translation
Client Workshop
Contingency Management and Client Research
Health Care Intervention
Mentoring and Youth Groups
Needle and Syringe Programme
Volunteer Expenses
Partner Payments
Payments to Joint Providers
Premises Costs
Premises Costs		 Charitable
activities
£
8,784
-
2,136
2,018,950
589
17,854
17,512
2,065,825
23,736
9,511
8,733
2,916
35,952
5,183
196,638
3,385
286,054
981,176
981,176
182,470
182,470		 Support and
governance
costs
£
-
2,846
-
64,797
-
106
-
67,749
-
-
-
-
-
-
-
-
-
-
-
-
-		 2022 Total
£
8,784
2,846
2,136
2,083,747
589
17,960
17,512
2,133,574
23,736
9,511
8,733
2,916
35,952
5,183
196,638
3,385
286,054
981,176
981,176
182,470
182,470

40

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2022

7. Expenditure on charitable activities (continued)

Other Costs
Audit Fees
Bank Charges
Depreciation
Equipment Hire
Health, Safety and Welfare
Insurance
IT Costs and Support
Marketing and Events
Non Capital Equipment
Other
Printing, Postage and Stationery
Professional Fees and Consultancy
Subscriptions
Telephone Charges
Sub-total
Allocation of support and governance costs
Total expenditure		 Charitable
activities
£
-
718
10,569
4,531
11,080
16,565
27,823
14,027
8,277
65
10,903
23,410
882
13,155
142,005
3,657,530
77,234
3,734,764		 Support and
governance
costs
£
8,760
-
-
-
-
725
-
-
-
-
-
-
-
-
9,485
77,234
(77,234)
-		 2022 Total
£
8,760
718
10,569
4,531
11,080
17,290
27,823
14,027
8,277
65
10,903
23,410
882
13,155
151,490
3,734,764
-
3,734,764

Total governance costs were £12,437 (2021: £10,544).

41

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2022

7. Expenditure on charitable activities (continued) Prior year comparative

Staff Costs
External Supervision
Legal and Professional
Recruitment
Salaries, Employer's NI and Pensions
Staff Benefits and Childcare Vouchers
Training and Development
Travel and Subsistence
Direct Service Costs
Breaking Free/SARI
Client Service Access and Translation
Client Workshop
Contingency Management and Client Research
Health Care Intervention
Mentoring and Youth Groups
Needle and Syringe Programme
Volunteer Expenses
Partner Payments
Payments to Joint Providers
Premises Costs
Premises Costs		 Charitable
activities
£
7,458
-
363
1,980,311
5,428
6,341
11,393
2,011,294
19,320
2,552
7,145
7,262
30,579
4,198
156,003
1,567
228,626
965,787
965,787
156,723
156,723		 Support and
governance
costs
£
-
1,290
-
60,372
-
-
-
61,662
-
-
-
-
-
-
-
-
-
-
-
-
-		 2021 Total
£
7,458
1,290
363
2,040,683
5,428
6,341
11,393
2,072,956
19,320
2,552
7,145
7,262
30,579
4,198
156,003
1,567
228,626
965,787
965,787
156,723
156,723

42

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2022

7. Expenditure on charitable activities (continued)

Other Costs
Audit Fees
Bank Charges
Depreciation
Equipment Hire
Health, Safety and Welfare
Insurance
IT Costs and Support
Marketing and Events
Non Capital Equipment
Other
Printing, Postage and Stationery
Professional Fees and Consultancy
Provision for Liabilities
Subscriptions
Telephone Charges
Sub-total
Allocation of support and governance costs
Total expenditure		 Charitable
activities
£
-
720
16,352
6,039
7,847
15,080
22,571
14,426
7,372
9,754
13,201
22,756
51,584
501
15,034
203,237
3,565,667
70,916
3,636,583		 Support and
governance
costs
£
8,400
-
-
-
-
628
-
-
-
226
-
-
-
-
-
9,254
70,916
(70,916)
-		 2021 Total
£
8,400
720
16,352
6,039
7,847
15,708
22,571
14,426
7,372
9,980
13,201
22,756
51,584
501
15,034
212,491
3,636,583
-
3,636,583

43

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2022

8. Tangible fixed assets

Cost
At 1 April 2021 and at 31 March 2022
Depreciation
At 1 April 2021
Charge for the year
At 31 March 2022
Net book value
At 31 March 2022
At 31 March 2021
Investments
Investments in associates		 Motor
vehicles
£
63,832
63,832
-
63,832
-
-		 £
293,907
266,803
10,569
277,372
16,535
27,104
2022
£
16,000
Fixtures,
fittings and
computer
equipment		 Total
2022
£
357,739
330,635
10,569
341,204
16,535
27,104
2021
£
16,000

9. Investments

Details of undertakings

Details of the investments in which the group holds 20% or more of the nominal value of any class of share capital are as follows:

Country of Proportion of voting rights
Undertaking incorporation Holding and shares held
2022 2021
Social Impact Bristol England and Wales Ordinary 33% 33%
Limited Shares

The principal activity of Social Impact Bristol Limited is to work with some of Bristol's most entrenched rough sleepers. The address of its registered office is 5th Floor, 3 Thomas More Square, London, E1W 1YW.

Social Impact Bristol Limited’s contract with Bristol City Council ended on 31 March 2021 and the company ceased trading on that date. The Directors have commenced proceedings to wind up the company. Upon wind up, any remaining funds will be distributed to investors.

44

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2022

10. Debtors
Amounts falling due within 1 year
Trade debtors
Prepayments
Other debtors
Amounts falling due after more than 1 year
Rent and deposits
11. Creditors
Amounts falling due within 1 year
Trade creditors
Accruals
Other taxation and social security
Deferred income (see below)
Other creditors
The movement in deferred income was as follows:
Balance at beginning of year
Released during the year
Deferred during the year
Balance at end of year		 2022
£
41,690
31,684
6,308
79,682
1,300
80,982
2022
£
178,789
145,245
36,660
196,586
110,878
668,158
2022
£
47,237
(12,712)
162,061
196,586		 2021
£
278,364
29,088
8,689
316,141
1,300
317,441
2021
£
159,553
30,265
49,333
47,237
8,845
295,233
2021
£
31,896
(31,896)
47,237
47,237

Deferred income relates to income received in advance of delivery of services.

45

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2022

12. Provision for liabilities

Provision for lease dilapidation 2022
£
166,000		 2021
£
166,000

Included within the leases for the charity's rented premises are dilapidation clauses. The trustees consider they are able to quantify the expected cost of the lease dilapidations, and have consequently included a provision of £166,000 (2021: £166,000) in the accounts. The amount recognised as an expense during the year was £nil (2021: £51,584).

13. Guarantees and other financial commitments

The charity had operating leases at the year end with total future minimum lease payments as follows:

Amount falling due:
Within 1 year
Within 1 - 5 years		 2022
£
64,558
91,875
156,433		 2021
£
66,286
128,625
194,911

14. Analysis of net assets between funds

General
funds
2022
£
Tangible fixed assets
16,535
Investments
16,000
Current assets
4,109,102
Current liabilities
(277,562)
Provisions
(166,000)
Total net assets at 31 March 2022
3,698,075
Prior year comparative
General
funds
2021
£
Tangible fixed assets
27,104
Investments
16,000
Current assets
3,980,442
Current liabilities
(110,607)
Provisions
(166,000)
Total net assets at 31 March 2021
3,746,939		 Desingated
funds
2022
£
-
-
9,617
-
-
9,617
2021
£
-
-
(856)
-
-
(856)
Desingated
funds		 Restricted
funds
2022
£
-
-
667,394
(390,596)
-
276,798
2021
£
-
-
335,416
(184,626)
-
150,790
Restricted
funds		 Total funds
2022
£
16,535
16,000
4,786,113
(668,158)
(166,000)
3,984,490
Total funds
2021
£
27,104
16,000
4,315,002
(295,233)
(166,000)
3,896,873

46

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2022

15. Movement in funds

Movement in funds
Restricted funds
ADDER
Children's Youth Group (M32)
New Leaf
ROADS APPS/SMART
ROADS Complex Needs
Veterans
Total restricted funds
Unrestricted funds
Designated funds:
50+ Get Back Out There
Golden Key Service Coordinator
New Leaf Rapid
Special Allocation Service
Targeted Youth Service
Youth Alcohol Drug Diversion
Total designated funds
General funds
Total unrestricted funds
Total funds
ROADS Early Engagement &
Intervention
ROADS Substance Misuse
Liaison
Street Intervention Service
Substance Misuse Liaison
Connect		 At 1 April
2021
£
-
12,424
40,615
406
-
48,807
17,207
2,044
-
29,287
150,790
-
(856)
-
-
-
-
(856)
3,746,939
3,746,083
3,896,873		 Income
£
212,172
10,000
(11,142)
257,519
650,968
996,650
1,372,474
35,000
62,051
-
3,585,692
8,190
9,204
8,501
7,924
142,144
2,712
178,675
58,014
236,689
3,822,381		 £
(211,091)
(15,216)
(29,473)
(257,402)
(650,968)
(913,418)
(1,279,700)
(37,044)
(62,051)
(3,321)
(3,459,684)
(1,676)
(8,348)
(5,398)
(7,924)
(147,602)
(2,712)
(173,660)
(101,420)
(275,080)
(3,734,764)
Expenditure		 £
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
5,458
-
5,458
(5,458)
-
-
Transfers
between
funds		 £
1,081
7,208
-
523
-
132,039
109,981
-
-
25,966
At 31 March
2022
276,798
6,514
-
3,103
-
-
-
9,617
3,698,075
3,707,692
3,984,490

47

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2022

15. Movement in funds (continued) Purposes of restricted funds:

ADDER (Addiction, Diversion, Disruption, Enforcement & Recovery)

Part of a multimillion pound investment and a system-wide programme that focus on co-ordinated law enforcement activity, alongside expanded diversionary programs using the criminal justice system to divert people away from offending.

Children's Youth Group (M32)

Funding from Nisbet Trust, to continue running our Youth Groups for children and young people whose mum, dad or sibling’s alcohol or drug use is problematic.

New Leaf

CHK Foundation provided a further grant in March 2021 to continue support for a Youth Worker role working with young people using cannabis use and at risk of Child Criminal Exploitation for the period of 12 months ending February 2022.

Recovery Orientated Alcohol & Drugs Service (ROADS):

Street Intervention Service

Now funded by Rough Sleeping Drug and Alcohol Treatment Grant (RSDATG), initially funded by ROADS within Bristol City Council’s Street Intervention Service (SIS). The SIS’s priority is to reduce Antisocial Behaviour through a combination of support and enforcement activity.

Substance Misuse Liaison Connect

Project staff funded by Rough Sleeping Drug and Alcohol Treatment Grant (RSDATG) to support the delivery of OST to homeless service users and without a GP.

Veterans

Donation from the Youngwood Trust enabling continuation of the Veteran Support Worker role from May 2020. After reviewing the veterans support organisations capacity to engage during the covid restrictions, it was agreed with the donor to pause this activity until a later date, not yet decided.

48

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2022

15. Movement in funds (continued)

Purposes of designated funds:

50+ Get Back Out There - Funding made available by St Monica's Trust to Support Hub Partnership of which BDP is a member, to support our Get Back Out There 50+ Group.

Golden Key funding is part of the Big Lottery’s ‘Fulfilling Lives’ investment in Bristol to improve services and outcomes for people with complex needs who are experiencing at least three of the following: alcohol or drug misuse, homelessness, mental ill health, offending. The lead agency is Second Step and BDP is one of a number of local organisations employing and seconding a Service Co-ordinator post to the Golden Key team. This project ended in June 2021.

New Leaf Rapid following a successful application through Vanguard (BNSSG Integrated Care Board), New Leaf Rapid has funding for 3 full time workers for 2 years. The pilot year is in Bristol and year 2 extended to South Gloucestershire and North Somerset. NLR works with Violence Reductions Units’ (Safer Options in Bristol), Education Inclusion Managers to harness a Drugs in School Pathway to reduce school exclusions for substance use or behaviours resulting from Children Affected By Substances trauma.

Special Allocation Service (formerly known as Tackling Violence Service): BDP is providing support to people with drug and alcohol dependence who are engaged with this primary health care service.

Targeted Youth Service: BDP delivers an element of this new service, sub-contracted by Creative Youth Network, focused on young people’s alcohol and drug use, aged 11-19 years. The trustees have agreed to use General Funds for the shortfall of funding towards the performance of Targeted Youth Service.

Youth Alcohol Drug Diversion (formerly Youth Drugs Education) offers young people under 18 years arrested for first time possession of a substance controlled under the Misuse of Drugs Act, the opportunity to engage with a structured individual intervention with BDP as an alternative to a criminal justice disposal.

49

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2022

15. Movement in funds

Prior period comparative
Restricted funds
50+ Transformation Grant
Children's Youth Group (M32)
Creative Communities
New Leaf
RBL Capacity Building Grant
ROADS APPS/SMART
ROADS Complex Needs
Veterans
Total restricted funds
Unrestricted funds
Designated funds:
Covid 19 designated funds
Entrenched Rough Sleepers
Golden Key Service Coordinator
Special Allocation Service
Targeted Youth Service
Youth Alcohol Drug Diversion
Total designated funds
General funds
Total unrestricted funds
Total funds
ROADS Street Intervention
ROADS Substance Misuse
ROADS Early Engagement &		 At 1 April
2020
£
3,751
10,713
919
27,711
3,686
683
-
(9,164)
213
301
40,000
78,813
-
1,354
324
-
-
815
2,493
3,745,684
3,748,177
3,826,990		 Income
£
1,403
13,801
9,105
30,000
-
257,520
636,304
1,003,108
35,000
1,372,474
6,250
3,364,965
8,202
79,328
36,817
7,750
143,451
1,913
277,461
64,040
341,501
3,706,466		 £
(6,185)
(12,090)
(10,008)
(17,096)
(3,686)
(257,797)
(636,304)
(945,137)
(33,169)
(1,355,568)
(16,963)
(3,294,003)
(8,012)
(30,967)
(37,997)
(7,750)
(166,923)
(2,728)
(254,377)
(88,203)
(342,580)
(3,636,583)
Expenditure		 £
1,031
-
(16)
-
-
-
-
-
-
-
-
1,015
(190)
(49,715)
-
-
23,472
-
(26,433)
25,418
(1,015)
-
Transfers
between
funds		 £
-
12,424
-
40,615
-
406
-
48,807
2,044
17,207
29,287
At 31 March
2021
150,790
-
-
(856)
-
-
-
(856)
3,746,939
3,746,083
3,896,873

50

Bristol Drugs Project Limited

Notes to the financial statements

For the year ended 31 March 2022

16. Called up share capital

There is no share capital as the company is limited by guarantee. In the event of the charity being wound up the liability in respect of the guarantee is limited to £1 per member of the charity as stated in the Memorandum and Articles of Association.

17. Related party transactions

During the year, the charity made the following related party transactions:

Social Impact Bristol Limited (an investment of the charity) – during the year, the charity received income of £nil (2021: £29,548) and a gift aid donation of £6,251 (2021: £49,780) from Social Impact Bristol Limited. At the balance sheet date, the amount due from Social Impact Bristol Limited was £nil (2021: £nil). BDP's CEO, Maggie Telfer, is a Director of Social Impact Bristol Limited.

Michael Lea, Trustee, was also a Trustee of Creative Youth Network (until 7 September 2021) with whom BDP have a sub-contract and receive funds to deliver the Targeted Youth Service.

51